NCT01552356 2026-04-13
Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
10 trialsNCT01575548 2026-04-13
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01841736 2026-04-13
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02180867 2026-04-13
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT01684397 2026-02-27
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Roswell Park Cancer Institute
Phase 1/2 Active not recruiting
NCT05180695 2026-02-10
AMPHISARC
Centre Leon Berard
Phase 1/2 Active not recruiting
NCT01217931 2026-01-30
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05210413 2026-01-15
SPARTO
University Hospital, Bordeaux
Phase 1/2 Active not recruiting
NCT06263231 2025-07-29
INVINCIBLE-3
Intensity Therapeutics, Inc.
Phase 3 Active not recruiting
NCT02203760 2024-11-15
PazoDoble
North Eastern German Society of Gynaecological Oncology
Phase 2 Active not recruiting